文献速递认知障碍与痴呆

70岁以上社区居住人群中符合仑卡奈单抗启动治疗条件的比例:哥德堡H70出生队列研究

Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation: The Gothenburg H70 Birth Cohort Study.
PubMed 文献 · Neurology · 2024-04-09

基于哥德堡H70出生队列中70岁人群的临床数据、脑脊液β淀粉样蛋白42和脑MRI,评估符合FDA批准的仑卡奈单抗治疗条件的比例。290名参与者中30人(10.3%)符合治疗指征,其中18人(6.2%)符合条件且无特殊考虑因素。

要点

  • 290名70岁参与者中30人(10.3%)符合仑卡奈单抗治疗指征,18人(6.2%)符合条件且无特殊考虑因素。
  • 作者认为本研究为更大规模的比例研究和仑卡奈单抗治疗的实施提供了信息。

核心结论

  • 290名70岁参与者中30人(10.3%)符合仑卡奈单抗治疗指征,其中18人(6.2%)符合条件且无特殊考虑因素。
  • 作者认为本研究为更大规模的比例研究和仑卡奈单抗治疗的实施提供了信息。

研究设计与样本

  • 基于哥德堡H70出生队列研究中具有临床数据、脑脊液β淀粉样蛋白42和脑MRI分析的参与者,按FDA批准的建议评估接受仑卡奈单抗治疗的资格,并记录需要特殊考虑的因素。
  • 利用公开人口统计数据将结果外推至欧洲和美国符合条件的人数。

主要发现

  • 290名参与者中30人(10.3%)符合治疗指征,其中18人(6.2%)符合条件且无特殊考虑因素。

关键数值与推荐

  • 符合治疗指征:290名参与者中30人(10.3%)。
  • 符合条件且无特殊考虑因素:290名参与者中18人(6.2%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the prevalence of individuals with Alzheimer disease (AD) eligible for treatment with the recently FDA-approved lecanemab based on data from a population-based sample of 70-year-olds and extrapolate an estimation of individuals eligible in Europe and the United States. METHODS: Participants from the Gothenburg H70 Birth Cohort Study with clinical data, CSF-amyloid beta 42, and brain MRI analysis were evaluated for eligibility to receive lecanemab treatment according to FDA-approved recommendations, noting factors requiring special consideration. Results were used to extrapolate the number of eligible individuals in Europe and the United States using public demographic data. RESULTS: Thirty (10.3%) of 290 participants met the indication for treatment of whom 18 (6.2%) were eligible and did not present factors requiring special consideration. Our estimate that 6.2% of all 70-year-olds in the full cohort are eligible for treatment extrapolates to an approximation that around 5.9 million Europeans and 2.2 million US residents could be eligible. DISCUSSION: Information on proportion of individuals eligible for AD treatment with lecanemab in the general public is limited. We provide information on 70-year-olds in Sweden and extrapolate these data to Europe and the United States. This study opens for larger studies on this proportion and implementation of lecanemab treatment.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Dittrich A, Westman E, Shams S, et al. Proportion of Community-Dwelling Individuals Older Than 70 Years Eligible for Lecanemab Initiation: The Gothenburg H70 Birth Cohort Study. Neurology. 2024. PMID: 38593394. doi:10.1212/WNL.0000000000209402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。